These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25084176)

  • 1. Biomarkers of interferon Beta therapy in multiple sclerosis.
    Graber JJ; Dhib-Jalbut S
    J Interferon Cytokine Res; 2014 Aug; 34(8):600-4. PubMed ID: 25084176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis.
    Lynch SG; Rose JW
    Dis Mon; 1996 Jan; 42(1):1-55. PubMed ID: 8556963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on managing patients with multiple sclerosis in primary care.
    Hardeman P
    JAAPA; 2024 Feb; 37(2):22-29. PubMed ID: 38230895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis.
    Dimisianos N; Rodi M; Kalavrizioti D; Georgiou V; Papathanasopoulos P; Mouzaki A
    Mult Scler Int; 2014; 2014():436764. PubMed ID: 25152817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of therapeutic response in multiple sclerosis: current status.
    Harris VK; Sadiq SA
    Mol Diagn Ther; 2014 Dec; 18(6):605-17. PubMed ID: 25164543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis: current knowledge and future outlook.
    Kamm CP; Uitdehaag BM; Polman CH
    Eur Neurol; 2014; 72(3-4):132-41. PubMed ID: 25095894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F; Chiarini M; Sottini A; Bertoli D; Giustini V; Tessitore MV; Caimi L; Capra R; Imberti L
    J Neuroimmunol; 2014 Dec; 277(1-2):6-12. PubMed ID: 25468273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.
    Freedman MS; Comi G; De Stefano N; Barkhof F; Polman CH; Uitdehaag BM; Lehr L; Stubinski B; Kappos L
    Mult Scler Relat Disord; 2014 Mar; 3(2):147-55. PubMed ID: 25878002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.
    Baranzini SE; Madireddy LR; Cromer A; D'Antonio M; Lehr L; Beelke M; Farmer P; Battaglini M; Caillier SJ; Stromillo ML; De Stefano N; Monnet E; Cree BA
    Mult Scler; 2015 Jun; 21(7):894-904. PubMed ID: 25392319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments.
    Luchtman DW; Ellwardt E; Larochelle C; Zipp F
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):403-13. PubMed ID: 25153998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence of disease activity after repeated Natalizumab withdrawals.
    Ferrè L; Moiola L; Sangalli F; Radaelli M; Barcella V; Comi G; Martinelli V
    Neurol Sci; 2015 Mar; 36(3):465-7. PubMed ID: 25249399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.
    Cohen JA; Krishnan AV; Goodman AD; Potts J; Wang P; Havrdova E; Polman C; Rudick RA
    JAMA Neurol; 2014 Nov; 71(11):1386-93. PubMed ID: 25178496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation.
    Fragoso YD
    Expert Opin Drug Saf; 2014 Dec; 13(12):1743-8. PubMed ID: 25176273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
    Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.
    Caporro M; Disanto G; Gobbi C; Zecca C
    Patient Prefer Adherence; 2014; 8():1123-34. PubMed ID: 25170258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent Atrioventricular Block following Fingolimod Initiation.
    Gialafos E; Gerakoulis S; Grigoriou A; Haina V; Kilidireas C; Stamboulis E; Andreadou E
    Case Rep Neurol Med; 2014; 2014():191305. PubMed ID: 25161784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?
    Lee JY; Taghian K; Petratos S
    Acta Neuropathol Commun; 2014 Aug; 2():97. PubMed ID: 25159125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab.
    Beume LA; Dersch R; Fuhrer H; Stich O; Rauer S; Niesen WD
    J Clin Neurosci; 2015 Feb; 22(2):400-1. PubMed ID: 25150761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.
    Muris AH; Rolf L; Damoiseaux J; Koeman E; Hupperts R
    BMC Neurol; 2014 Aug; 14():164. PubMed ID: 25138918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Kostadinova II
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.